- Home
- CLLS vs EDD Comparison
CLLS vs EDD Comparison
Compare CLLS & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | EDD |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 337.7M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | EDD |
|---|---|---|
| Price | $1.25 | $5.34 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.33 | N/A |
| AVG Volume (30 Days) | 191.3K | ★ 390.9K |
| Earning Date | 11-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $4.96 |
| 52 Week High | $5.48 | $6.18 |
Technical Indicators
Market Signals| Indicator | CLLS | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 21.90 | 40.10 |
| Support Level | $1.25 | $4.96 |
| Resistance Level | $2.99 | $5.66 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 7.63 | 28.77 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.